Irinotecan for children with relapsed solid tumors

Toshiji Shitara, Akira Shimada, Ryoji Hanada, Tadashi Matsunaga, Keisei Kawa, Hideo Mugishima, Tohru Sugimoto, Jun Ichi Mimaya, Atsushi Manabe, Masahito Tsurusawa, Yoshiaki Tsuchida

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

Original languageEnglish
Pages (from-to)103-110
Number of pages8
JournalPediatric Hematology and Oncology
Issue number2
Publication statusPublished - Mar 2006
Externally publishedYes


  • Clinical trials
  • Irinotecan
  • Nephroblastoma
  • Neuroblastoma
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Irinotecan for children with relapsed solid tumors'. Together they form a unique fingerprint.

Cite this